Tacrolimus

證據等級: L5

預測適應症: 3 個

Tacrolimus: From Atopic Dermatitis to Seborrheic Dermatitis

One-Sentence Summary

Tacrolimus (Protopic®) is a topical calcineurin inhibitor established globally for atopic dermatitis, working by blocking T-cell-driven inflammatory cascades — though it is currently not registered in the Philippines. The TxGNN model predicts it may be effective for Seborrheic Dermatitis, with 2 completed clinical trials (including a Phase 3 RCT) and 20 publications supporting this direction. Evidence strength reaches L1 — the highest tier — making this one of the strongest repurposing candidates in this analysis.

Quick Overview

Item	Content
Original Indication	Atopic Dermatitis (established global indication; not registered in the Philippines)
Predicted New Indication	Seborrheic Dermatitis
TxGNN Prediction Score	99.26%
Evidence Level	L1
Philippines Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Tacrolimus binds to the intracellular immunophilin FKBP12, forming a complex that inhibits calcineurin — the phosphatase responsible for dephosphorylating NFAT (Nuclear Factor of Activated T-cells). By blocking NFAT nuclear translocation, tacrolimus suppresses transcription of key pro-inflammatory cytokines including IL-2, IL-4, and TNF-α. As a topical ointment, it achieves targeted immunomodulation in the skin without the systemic exposure or local side effects (particularly skin atrophy and telangiectasia) that limit long-term use of topical corticosteroids.

Seborrheic dermatitis is a chronic, relapsing inflammatory condition affecting sebaceous-gland-rich areas such as the face and scalp. While colonization by the lipophilic yeast Malassezia is the primary environmental trigger, the tissue damage arises from the resulting Th-cell-mediated immune response — the same calcineurin–NFAT pathway that tacrolimus directly inhibits. The mechanistic bridge between atopic dermatitis and seborrheic dermatitis is therefore not superficial: both diseases share the same downstream inflammatory mediator cascade that tacrolimus is designed to block.

There is also a strong clinical rationale specific to seborrheic dermatitis. The face is the most commonly affected site, yet it is also the area most vulnerable to steroid-induced adverse effects with prolonged use. Tacrolimus’s steroid-sparing profile makes it uniquely suitable for facial seborrheic dermatitis maintenance — a use case directly supported by the Phase 3 and Phase 4 trials in this evidence pack and by published RCT results in the Journal of the American Academy of Dermatology (2021).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02004860	Phase 3	Completed	120	Evaluated tacrolimus ointment (Protopic®) for maintenance treatment of severe seborrheic dermatitis on the adult face; assessed capacity to reduce relapse frequency, prolong remission, and reduce dependence on topical steroids. Results published as a multicenter double-blind RCT (Joly et al., JAAD 2021).
NCT01591070	Phase 4	Completed	104	Proactive use of 0.1% tacrolimus ointment once or twice weekly in adult facial seborrheic dermatitis; demonstrated that intermittent application can maintain remission and significantly reduce exacerbation incidence in real-world clinical practice.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33010323	2021	Multicenter RCT	J Am Acad Dermatol	Tacrolimus 0.1% vs. ciclopiroxolamine 1% for maintenance of severe facial SD; multicenter, double-blind, randomized design — this is the primary publication of NCT02004860, providing the highest-grade direct evidence for the predicted indication
24171300	2013	Comparative RCT	Ann Parasitol	Head-to-head RCT (n=60) comparing tacrolimus 0.03% cream vs. sertaconazole 2% cream in seborrheic dermatitis; directly evaluates anti-inflammatory vs. antifungal treatment strategies
26512166	2015	Prospective Clinical Trial	Ann Dermatol	Maintenance therapy with 0.1% tacrolimus ointment for facial seborrheic dermatitis; demonstrated feasibility of low-dose intermittent calcineurin inhibitor regimen adapted from atopic dermatitis maintenance protocols
39219446	2024	Cochrane Systematic Review / NMA	Clin Exp Allergy	Network meta-analysis of topical anti-inflammatory treatments for eczema conditions; contextualizes tacrolimus within the current landscape of topical immunomodulators including comparative safety and efficacy
19222250	2009	Review	Am J Clin Dermatol	Comprehensive review of topical calcineurin inhibitors specifically for seborrheic dermatitis; summarizes pathophysiology, safety, and efficacy evidence and supports TCIs as a safe alternative to corticosteroids
27804089	2017	Systematic Review	Am J Clin Dermatol	Systematic review of topical treatments for facial seborrheic dermatitis; positions tacrolimus alongside antifungals and keratolytics as a validated treatment option
12833030	2003	Open Pilot Study	J Am Acad Dermatol	Earliest proof-of-concept study: 18 SD patients treated with 0.1% tacrolimus for 28 days; 61% achieved 100% clearance — established the initial clinical signal for the SD indication
15461548	2004	Review	Expert Opin Pharmacother	Tacrolimus ointment for atopic dermatitis and other inflammatory cutaneous diseases; reviews calcineurin inhibition mechanism and its applicability across multiple inflammatory skin conditions including SD
37067129	2023	Clinical Study	Indian J Dermatol Venereol Leprol	Oral itraconazole (2 days) plus topical tacrolimus vs. topical tacrolimus alone for SD maintenance in Vietnam; evaluates combination strategies in a Southeast Asian real-world setting directly relevant to the Philippines context
19213227	2009	Narrative Review	J Drugs Dermatol	Overview of facial seborrheic dermatitis etiology, epidemiology, and therapeutic horizons; contextualizes the role of calcineurin inhibitors within the evolving SD treatment paradigm

Philippines Market Information

Tacrolimus is currently not registered with the Food and Drug Administration of the Philippines (FDA Philippines). No authorization records are available for any product, dosage form, or indication.

Note: Tacrolimus ointment (Protopic®) is approved in multiple jurisdictions — including the US FDA, EMA, Japan PMDA, and Taiwan TFDA — for atopic dermatitis, and in some countries for seborrheic dermatitis maintenance. A new product registration application to FDA Philippines would be required before any local commercial use.

Safety Considerations

Please refer to the package insert for safety information.

Formal safety data — including label warnings, contraindications, and drug–drug interaction profiles — are not available in this evidence pack. The TFDA package insert (or equivalent from FDA Philippines-recognized jurisdictions) must be reviewed before proceeding to any clinical or regulatory planning stage.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence base for tacrolimus in seborrheic dermatitis is strong and directly relevant: a completed multicenter Phase 3 RCT (NCT02004860, n=120), a Phase 4 real-world study (NCT01591070, n=104), a published multicenter double-blind RCT in JAAD (2021), and a well-established mechanistic link through calcineurin–NFAT inhibition of Th-cell-driven skin inflammation. However, tacrolimus holds zero registrations in the Philippines, making regulatory submission the immediate gating step before any local market development.

To proceed, the following is needed:

Safety documentation: Obtain the Protopic® package insert (or EMA/FDA SmPC) to extract warnings, contraindications, and drug–drug interactions; this currently blocks the formal safety screening stage
MOA documentation: Retrieve complete mechanism-of-action data from DrugBank or published pharmacology literature to support the regulatory dossier
FDA Philippines registration: Conduct a regulatory gap analysis and prepare a new product registration (NPR) application, which may incorporate both the established atopic dermatitis indication and the seborrheic dermatitis evidence package
Local clinical evidence: Consider a bridging study or post-market study in Filipino patients, particularly given the Southeast Asian relevance demonstrated by the 2023 Vietnam study (PMID 37067129)
Pharmacovigilance plan: Establish monitoring protocols for known tacrolimus topical risks (application-site burning/stinging, and long-term immunosuppression considerations for sensitive facial skin areas)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.